HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 09-02-2022, 09:38 AM   #1
Nguyen
Senior Member
 
Join Date: Nov 2005
Posts: 425
Enhertu and interstitial lung disease

Pooled analysis of drug-related interstitial lung disease and/or pneumonitis
in nine trastuzumab deruxtecan monotherapy studies

https://www.esmoopen.com/action/show...2822%2900182-X

Introduction: This pooled analysis of nine phase I and II trastuzumab deruxtecan (T-DXd) monotherapy studies
described drug-related interstitial lung disease (ILD)/pneumonitis in patients treated with T-DXd.

Methods: Patients who received T-DXd across nine studies were included. Investigator-assessed ILD/pneumonitis events
were retrospectively reviewed by an independent adjudication committee; events adjudicated as drug-related ILD/
pneumonitis are summarized.

Results: The analysis included 1150 patients (breast cancer, 44.3%; gastric cancer, 25.6%; lung cancer, 17.7%; colorectal
cancer, 9.3%; other cancer, 3.0%). Median treatment duration was 5.8 (range, 0.7-56.3) months, with a median of 4
(range, 1-27) prior lines of therapy. The overall incidence of adjudicated drug-related ILD/pneumonitis was 15.4%
(grade 5, 2.2%). Most patients with ILD/pneumonitis experienced low-grade events (grade 1 or 2, 77.4%); 87.0%
had their first event within 12 months [median, 5.4 (range, <0.1-46.8) months] of their first dose of T-DXd. Based
on data review, adjudicated ILD/pneumonitis onset occurred earlier than identified by investigators for 53.2% of
events [median difference in onset date, 43 (range, 1-499) days]. Stepwise Cox regression identified several baseline
factors potentially associated with increased risk of adjudicated drug-related ILD/pneumonitis: age <65 years,
enrollment in Japan, T-DXd dose >6.4 mg/kg, oxygen saturation <95%, moderate/severe renal impairment,
presence of lung comorbidities, and time since initial diagnosis >4 years.

Conclusions: In this pooled analysis of heavily treated patients, the incidence of ILD/pneumonitis was 15.4%, with most
being low grade and occurring in the first 12 months of treatment. The benefiterisk of T-DXd treatment is positive;
however, some patients may be at increased risk of developing ILD/pneumonitis, and further investigation is needed
to confirm ILD/pneumonitis risk factors. Close monitoring and proactive management of ILD/pneumonitis are
warranted for all.
Nguyen is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 02:13 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2022, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter